Literature DB >> 2856742

Disparate cardiac effects of afterload reduction in hypertension.

C Amodeo1, F H Messerli, H O Ventura, I Kobrin, G Garavaglia, B Nuñez, E D Frohlich.   

Abstract

Cardiac performance, as judged by preload, afterload, and myocardial contractility, was evaluated by non-invasive M-mode echocardiography before and after acute oral administration of calcium entry blockers (nitrendipine and verapamil), angiotensin converting enzyme (ACE) inhibitors (captopril and lisinopril), and a dopamine receptor agonist (fenoldopam) in patients with mild to moderate essential hypertension. Left ventricular end diastolic volume was taken as an index of preload, end systolic stress as an index of afterload, and the ratio of systolic pressure to end systolic volume (SBP:ESV), ejection fraction (EF), and mean velocity of circumferential fibre shortening (Vcf) as indices of contractility. Reductions of afterload and mean arterial pressure were achieved with all antihypertensive agents involved (mean percentage change +/- s.e.m.: 15 +/- 2% and 10 +/- 1%, respectively, P < 0.05) but the afterload reduction with lisinopril was greatest (21 +/- 9%; P < 0.01). The dopamine receptor agonist fenoldopam decreased by preload 24% (P < 0.05) and increased all of the three parameters of myocardial contractility (SBP:SV 66%; EF 17%, Vcf 19%; P < 0.01). In contrast, no effect on these parameters was observed with either calcium entry blocker or either ACE inhibitor.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2856742

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  2 in total

1.  An updated concept for left ventricular hypertrophy risk in hypertension.

Authors:  Edward D Frohlich
Journal:  Ochsner J       Date:  2009

Review 2.  Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  S G Lancaster; P A Todd
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.